Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Bronchoscopy Market Size & Share 2026-2035
Report ID: GMI5249
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Bronchoscopy Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Bronchoscopy Market Size
The global bronchoscopy market was valued at USD 3.55 billion in 2025, is projected to reach USD 3.84 billion in 2026, and is forecast to expand at a 7.6% CAGR from 2026 to 2035, reaching USD 7.49 billion by 2035.
Bronchoscopy Market Key Takeaways
Market Leader: Olympus Corporation led with over 12.3% market share in 2025.
Leading Players: Top 5 players in this market include Olympus Corporation, Ambu A/S, Karl Storz, Johnson & Johnson, FUJIFILM Holdings, which collectively held a market share of 24.8% in 2025.
The global bronchoscopy market covers demand-side revenue from rigid and flexible bronchoscopes and directly associated biopsy, navigation, EBUS, cryobiopsy, and light-source consumables supplied to hospitals, ambulatory surgery centers, and specialty pulmonology clinics. Growth reflects a changing procedure mix: screening-led nodule detection is enlarging the diagnostic pathway, while single-use scopes and navigation-intensive procedures increase device content per intervention. Standalone software, reprocessing services, laryngoscopes, and GI endoscopy equipment remain outside this market definition.
GMI Analyst View
Based on our multi-year market assessment and direct industry inputs, the global bronchoscopy market generated USD 2.81 billion in 2022, establishing a consistent expansion baseline that preceded the current technology inflection in single-use and robotic-assisted procedures. This historic anchor validates the demand model underpinning our forward-looking framework and reflects that the market's trajectory is rooted in durable clinical need rather than cyclical rebound.
Bronchoscopy Market Trends, Growth Drivers & GMI Forecast Outlook
Bronchoscopy demand is moving beyond conventional visualization toward earlier lesion characterization, infection-control-driven workflow redesign, and image-guided peripheral access. The forecast depends on whether health systems can convert screening referrals into procedure capacity and whether reimbursement and training keep pace with higher-acuity navigation technologies.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Lung cancer screening broadens the pool of patients whose low-dose CT findings require tissue characterization, giving bronchoscopy a more recurring role in the diagnostic pathway rather than limiting it to symptom-led investigation. The commercial consequence is strongest for platforms that can navigate peripheral lesions, obtain representative samples, and integrate seamlessly into interventional pulmonology workflows.
Single-use adoption also rests on operational economics. Reusable flexible bronchoscopes require disciplined pre-cleaning, leak testing, manual channel cleaning, high-level disinfection, drying, and storage; deviations in this chain expose facilities to patient-safety and turnover risk [2]Current Pulmonology Reports. "Bronchoscopy-Related Infection and the Development of Single-Use Bronchoscopy Technology." link.springer.com. This makes disposable instruments particularly relevant to ICU, ASC, and lower-volume settings where maintaining a dedicated reprocessing operation is difficult.
Robotic navigation is shifting competition from optical hardware toward integrated procedure ecosystems. MONARCH QUEST and the Ion software update illustrate how AI-enabled navigation and intraprocedural imaging seek to reduce CT-to-body divergence during biopsy [5]Johnson & Johnson MedTech. "Johnson & Johnson MedTech Announces Clearance of MONARCH QUEST for Enhanced Robotic-Assisted Bronchoscopy." jnjmedtech.com[7]Intuitive Surgical. "Intuitive Expands AI and Advanced Imaging Integration in Ion Endoluminal System." investor.intuitivesurgical.com. Wider adoption, however, will depend on reimbursement recognition, capital availability, and a trained operator base.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Capacity is constrained not only by the availability of pulmonologists, but also by the narrower supply of clinicians able to perform advanced diagnostic and navigational interventions. This creates a self-reinforcing concentration of robotic and complex bronchoscopy in referral centers: the facilities most capable of training operators are also those most able to support capital-intensive platforms.
European hospital systems face an additional adoption challenge because workforce pressure can defer both procedure expansion and the credentialing needed for advanced systems. The health-workforce crisis therefore affects bronchoscopy through staffing, room utilization, and investment priorities, rather than merely through device purchasing budgets [4]European Parliament. "EU Legal Pathways for Addressing the Health Workforce Crisis." europarl.europa.eu.
Existing reprocessing infrastructure creates transition friction even where infection-control objectives favor disposable scopes. Facilities with established capital and trained reprocessing teams may retain reusable platforms for complex procedures, while greenfield ASCs can more readily build single-use pathways into their operating model.
GMI Analyst View
We view the forecast primarily as a change in technology and procedure mix rather than a simple expansion in case volume. Disposable scopes reshape lower-acuity workflow economics, while navigation systems raise the value of complex biopsy episodes. Reimbursement timing remains the principal variable that could delay broader robotic deployment without removing the underlying clinical demand.
Bronchoscopy Market Segment Analysis
By Product Type
The global bronchoscopy market remains centered on flexible platforms because they span routine diagnostics, therapeutic intervention, EBUS, and image-guided access. Product differentiation is increasingly determined by compatibility with navigation, imaging, and recurring consumables rather than by scope visualization alone.
Flexible Bronchoscopes
Flexible bronchoscopes generated USD 2.03 billion in 2025 and are projected to reach USD 4.19 billion by 2035. Their broad clinical utility across bedside airway evaluation, diagnostic sampling, EBUS-supported staging, and peripheral lesion work sustains their central position. Vendors are differentiating through image quality, working-channel functionality, and integration with navigation and single-use workflows.
Rigid Bronchoscopes
Rigid bronchoscopes held a 20.0% revenue share in 2025 and are forecast to grow at a 5.4% CAGR (2026-2035). The segment remains clinically essential for airway stenting, foreign-body extraction, severe hemoptysis, and other therapeutic interventions, but is concentrated in tertiary centers with anesthesia support and specialized operator skill. Its slower expansion reflects care-site concentration rather than reduced clinical relevance.
Other Product Types
Other product types, including accessories, navigation systems, sheaths, light sources, and cryobiopsy-related products, generated USD 814 million in 2025 and are anticipated to grow at a 10.0% CAGR (2026-2035). This category benefits directly from rising procedure complexity because every guided biopsy or interventional episode can require proprietary, procedure-specific content. The shift supports a recurring-revenue model in which consumables and navigation tools carry increasing strategic importance.
By Product Usage
Single-Use/Disposable
Single-use/disposable bronchoscopes generated USD 568 million in 2025 and are projected to reach USD 2.09 billion by 2035. Their appeal is strongest where sterile readiness, rapid turnover, and avoidance of reprocessing complexity matter most, including intensive-care, ASC, and high-acuity settings. The segment's advance is likely to be uneven, as instruments must continue to demonstrate capability in increasingly complex diagnostic and therapeutic applications.
Reusable
Reusable bronchoscopes represented an 84.0% revenue share in 2025 and are forecast to expand at a 6.1% CAGR (2026-2035). Their installed base, service relationships, and suitability for high-complexity interventions provide a durable foundation. Hospitals with established reprocessing operations are likely to retain reusable platforms for cases requiring extended procedure time, advanced ultrasound functionality, or demanding working-channel performance.
By Age Group
Adult
Adult bronchoscopy generated USD 3.12 billion in 2025 and is projected to reach USD 6.59 billion by 2035. Lung cancer, chronic respiratory disease, and the clinical needs of older populations make adult procedures the primary volume base for the market. Advanced staging and peripheral nodule evaluation further increase the importance of navigation-compatible flexible platforms in this cohort.
Pediatric
Pediatric bronchoscopy represented a 12.0% revenue share in 2025 and is forecast to grow at a 7.7% CAGR (2026-2035). Demand is shaped by congenital airway assessment, recurrent respiratory disease, and difficult airway management, with smaller-diameter instruments and infection-control considerations affecting purchasing decisions. Pediatric providers may be particularly receptive to disposable instruments where reprocessing small-diameter devices is operationally demanding.
GMI Analyst View
We see the strongest value migration occurring around the procedure, not the scope alone. Accessories, navigation tools, and disposable instruments can capture recurring revenue as clinicians pursue more complex lesions and care sites seek simpler workflows. Suppliers with connected platform and consumable portfolios are therefore better positioned than narrowly focused hardware providers.
Bronchoscopy Market Regional Analysis
North America Bronchoscopy Market Analysis
North America is the leading regional market within the Global Bronchoscopy Market, generating USD 1.34 billion in 2025 and projected to reach USD 2.66 billion by 2035. The region combines established interventional pulmonology capacity, advanced reimbursement infrastructure, and a large concentration of academic and ASC-based procedure settings. Screening-driven nodule detection and early adoption of disposable and robotic platforms make North America a critical proving ground for advanced bronchoscopy business models.
United States
The United States generated USD 1.26 billion in 2025, accounting for 93.5% of North American revenues and positioning the country as the single largest individual market in the global bronchoscopy sector. Its scale reflects dense specialist infrastructure, high-acuity referral centers, and a reimbursement environment that supports technology adoption. The country remains the leading commercial setting for robotic bronchoscopy, while ASCs and hospital outpatient departments provide an important channel for disposable-scope adoption.
Canada
Canada's market is shaped by provincial procurement systems and evidence-based technology assessment. Academic centers are likely to lead the adoption of advanced bronchoscopy technologies, while broader deployment depends on validation cycles and provincial capital priorities.
Europe Bronchoscopy Market Analysis
Europe generated USD 959 million in 2025 and is projected to expand at a 6.4% CAGR (2026-2035). Mature hospital infrastructure and broad clinical experience in EBUS and therapeutic bronchoscopy provide a stable demand base, but workforce constraints, capital-budget discipline, and device-access requirements can extend the adoption cycle for premium navigation platforms.
Germany
Germany generated USD 208 million in 2025 and accounted for 21.7% of European revenues. University hospital networks and established interventional pulmonology expertise support demand for EBUS, therapeutic bronchoscopy, and advanced diagnostics. The market is well positioned to benefit from a more structured national screening pathway as policy and implementation develop.
France
France generated USD 148 million in 2025 and represented 15.4% of European revenues. Its university hospital center networks provide an important base for diagnostic bronchoscopy and thoracic oncology referral, while centralized reimbursement assessment can lengthen the path for robotic and other premium technologies.
United Kingdom
The United Kingdom generated USD 140 million in 2025 and represented 14.6% of European revenues. NHS procurement emphasizes cost-effectiveness and scalable clinical evidence, making technology appraisal a decisive route-to-market factor. Targeted lung-health initiatives support an identifiable pipeline of patients needing diagnostic follow-up.
Italy
Italy generated USD 113 million in 2025. Bronchoscopy demand is concentrated in northern regional hospital systems and thoracic oncology centers, where procurement decisions vary by local health authority.
Spain
Spain generated USD 89 million in 2025. Rising referrals through the public health system support flexible bronchoscopy utilization, while adoption of higher-cost platforms remains sensitive to hospital investment cycles.
Netherlands
The Netherlands generated USD 63 million in 2025. Its advanced pulmonology care environment supports comparatively sophisticated use of EBUS-TBNA and related lung-cancer staging pathways.
Asia Pacific Bronchoscopy Market Analysis
Asia Pacific represented 26% of the global market in 2025 and is projected to reach USD 2.32 billion by 2035. The region combines substantial diagnostic need with divergent care-delivery models: China is expanding hospital capacity, Japan is a premium technology market, South Korea has high device utilization, and India is broadening access to pulmonary diagnostics. Asia accounted for 65.6% of global lung cancer cases, reinforcing the region's structural importance to bronchoscopy demand [1]IARC. "Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 34 Cancers in 186 Countries." iarc.who.int.
China
China generated USD 352 million in 2025 and represented 38.1% of Asia Pacific revenues. Hospital capacity expansion and evolving diagnostic expectations for lung cancer create demand across technology tiers, from accessible flexible scopes to advanced EBUS and navigation platforms. Competitive intensity spans domestic suppliers addressing public-hospital budgets and global vendors targeting premium centers.
Japan
Japan generated USD 257 million in 2025 and represented 27.8% of Asia Pacific revenues. Its dense pulmonology infrastructure and established reimbursement framework support adoption of advanced bronchoscopy. Olympus's BF-UCP190F launch across EMEA and Asia Pacific underscores continued focus on improved access for EBUS-guided sampling [6]Olympus Corporation. "Olympus Launches Latest EBUS Bronchoscope BF-UCP190F in EMEA and APAC." olympus-global.com.
South Korea
South Korea generated USD 102 million in 2025 and represented 11.1% of Asia Pacific revenues. High device utilization, responsive adoption dynamics, and a capable domestic medical-technology ecosystem support demand for advanced video bronchoscopy and EBUS platforms.
India
India generated USD 84 million in 2025 and represented 9.1% of Asia Pacific revenues. Investment in diagnostic infrastructure outside leading metropolitan centers is widening the opportunity for flexible bronchoscopy, while private hospitals are creating a more receptive channel for premium and disposable technologies.
Australia
Australia generated USD 72 million in 2025. Metropolitan specialist centers, established distribution networks, and ASC interest in single-use workflow models underpin the market's development.
Latin America Bronchoscopy Market Analysis
Latin America generated USD 178 million in 2025 and is forecast to grow at a 9.7% CAGR (2026-2035). Private hospital expansion and increasing access to pulmonary diagnostics support flexible bronchoscopy and EBUS demand, while public procurement cycles and macroeconomic conditions continue to influence capital-equipment adoption.
Brazil
Brazil generated USD 79 million in 2025 and accounted for 44.4% of Latin American revenues. Its private hospital networks and expanding interventional pulmonology capacity make it the region's principal market for advanced bronchoscopy investment. Flexible platforms remain central to the installed base, with disposable adoption developing in procedure-intensive settings.
Mexico
Mexico generated USD 51 million in 2025 and represented 28.7% of Latin American revenues. A dual public-private delivery model provides baseline demand for conventional flexible bronchoscopy while private hospitals create the main channel for advanced navigation and imaging systems.
Argentina
Argentina generated USD 20 million in 2025. The market has qualified specialist capability, but device procurement remains exposed to macroeconomic conditions and financing availability.
Middle East & Africa Bronchoscopy Market Analysis
Middle East & Africa represented 4% of the global market in 2025 and is projected to reach USD 310 million by 2035. Demand is being formed through specialist-hospital investment, referral-network development, and government-supported healthcare expansion, especially in Gulf markets. The region's growth profile remains sensitive to uneven availability of trained specialists and advanced procedural infrastructure.
Saudi Arabia
Saudi Arabia generated USD 36 million in 2025 and represented 25.4% of Middle East & Africa revenues. Specialist-capacity development and hospital investment linked to healthcare reform are expanding the setting for EBUS and lung-cancer staging procedures. Premium suppliers benefit where tertiary networks prioritize advanced respiratory services.
UAE
The UAE generated USD 31 million in 2025 and represented 21.8% of Middle East & Africa revenues. Internationally accredited private hospitals in Dubai and Abu Dhabi support demand for technology-led respiratory care and advanced bronchoscopy platforms.
South Africa
South Africa generated USD 25 million in 2025. Bronchoscopy demand is supported by the need for respiratory diagnosis and sampling across both public and private hospital environments.
GMI Analyst View
We expect Asia Pacific to exert the greatest influence on the global demand profile as capacity investment, technology adoption, and diagnostic need converge across several large markets. North America and Europe remain critical innovation and reimbursement markets, while Latin America and Middle East & Africa are building more durable specialist-care foundations that broaden the long-term opportunity.
Bronchoscopy Market Share & Competitive Landscape
The global bronchoscopy market share structure is fragmented, with the "others" category accounting for 67.5% of 2025 revenues. This reflects a broad base of regional manufacturers, accessory suppliers, biopsy-device specialists, and navigation providers serving distinct clinical niches. Leading competitors are responding by combining visualization platforms, procedure consumables, imaging, navigation, and service capabilities to protect recurring revenue around the intervention.
Olympus Corporation
Olympus Corporation generated USD 435 million in bronchoscopy-related revenue in 2025 and held a 12.3% market share. Its competitive position rests on a broad flexible, EBUS, and imaging portfolio, together with deeply established hospital relationships. The BF-UCP190F launch extends its EBUS offering toward segmental and subsegmental access, reinforcing the value of its installed platform ecosystem [6]Olympus Corporation. "Olympus Launches Latest EBUS Bronchoscope BF-UCP190F in EMEA and APAC." olympus-global.com.
Ambu A/S
Ambu A/S generated USD 210 million in bronchoscopy-related revenue in 2025 and held a 5.9% market share. The company is a central disruptive force in the disposable segment, where sterile readiness and simpler workflow are key commercial advantages. Its ability to build clinical intelligence and display-system integration alongside single-use scopes will determine how successfully it extends beyond convenience-led adoption.
Karl Storz
Karl Storz generated USD 108 million in bronchoscopy-related revenue in 2025 and held a 3.0% market share. Its strength in rigid bronchoscopy and precision instrumentation gives it a defensible position in specialized thoracic intervention, where operator familiarity and procedural reliability are significant qualification barriers.
Johnson & Johnson (Auris Health)
Johnson & Johnson (Auris Health) generated USD 72 million in 2025 from its bronchoscopy business. MONARCH QUEST's FDA clearance supports the company's strategy to compete through integrated robotic navigation, AI, and imaging capability rather than conventional scope hardware alone [5]Johnson & Johnson MedTech. "Johnson & Johnson MedTech Announces Clearance of MONARCH QUEST for Enhanced Robotic-Assisted Bronchoscopy." jnjmedtech.com. Commercial traction will depend on demonstrating a credible workflow and economic case for broader hospital adoption.
FUJIFILM Holdings
FUJIFILM Holdings generated USD 57 million in bronchoscopy-related revenue in 2025. The company competes principally through flexible bronchoscopy and imaging capabilities, particularly where its wider endoscopy relationships offer procurement and service advantages.
Hoya Corporation (Pentax Medical)
Hoya Corporation, through Pentax Medical, generated USD 54 million in 2025. Its service footprint and cost-competitive video bronchoscopy and EBUS alternatives support a defined role in hospital tenders where compatibility and lifecycle economics weigh heavily.
Broncus Medical
Broncus Medical generated USD 47 million in 2025. Its focused position in guided biopsy and therapeutic pulmonary intervention provides differentiation in indications where clinical specialization and proprietary systems can be more important than broad hardware scale.
Medtronic maintains a focused navigation position through LungVision and related respiratory accessories, offering an image-guided route for facilities seeking alternatives to more capital-intensive imaging configurations. Cook Medical remains strategically important in biopsy needles, guide sheaths, brushes, and other recurring consumables that are compatible with broad installed scope bases. Richard Wolf competes alongside Karl Storz in specialist rigid instrumentation, while Verathon, Teleflex, CONMED, Boston Scientific, Cogentix Medical, and other suppliers participate through airway visualization, accessories, or focused therapeutic and distribution channels.
Recent Industry Developments
Johnson & Johnson MedTech — MONARCH QUEST FDA Clearance (March 12, 2025). Johnson & Johnson MedTech received U.S. FDA 510(k) clearance for MONARCH QUEST, an update to its robotic-assisted bronchoscopy navigation technology. The system combines AI-enabled navigation with real-time CBCT imaging integration to address CT-to-body divergence during biopsy, strengthening the company's position in peripheral-lesion workflows [5]Johnson & Johnson MedTech. "Johnson & Johnson MedTech Announces Clearance of MONARCH QUEST for Enhanced Robotic-Assisted Bronchoscopy." jnjmedtech.com.
Olympus Corporation — BF-UCP190F EBUS Bronchoscope Launch (September 1, 2025). Olympus launched the BF-UCP190F across EMEA and major Asia Pacific markets. The new EBUS bronchoscope is designed to extend access for EBUS-TBNA-guided sampling in segmental and subsegmental bronchial areas while integrating with the company's existing EBUS platforms and ultrasound processors [6]Olympus Corporation. "Olympus Launches Latest EBUS Bronchoscope BF-UCP190F in EMEA and APAC." olympus-global.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →